Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #76 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Syncom Formulations (India) Limited (this stock) | 2,358 | 27.0 | 18.4% | 52.8% | 0.40% | 82 | 19 | 91 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 126 | 32 | 25 | ₹ |
| March 31, 2026 | 135 | 34 | 25 | ₹ |
| Dec. 31, 2025 | 115 | 25 | 19 | ₹ |
| Sept. 30, 2025 | 122 | 22 | 17 | ₹ |
| June 30, 2025 | 117 | 20 | 16 | ₹ |
| March 31, 2025 | 149 | 23 | 18 | ₹ |
| Dec. 31, 2024 | 128 | 17 | 13 | ₹ |
| Sept. 30, 2024 | 102 | 15 | 11 | ₹ |
| June 30, 2024 | 87 | 10 | 8 | ₹ |
| March 31, 2024 | 75 | 10 | 7 | ₹ |
| Dec. 31, 2023 | 65 | 9 | 7 | ₹ |
| Sept. 30, 2023 | 64 | 8 | 7 | ₹ |
| June 30, 2023 | 60 | 6 | 4 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 489 | 101 | 76 |
| March 31, 2025 | 465 | 66 | 49 |
| March 31, 2024 | 263 | 34 | 25 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 58 | -51 | -3 | 12 | 46 |
| March 31, 2025 | 23 | -18 | -68 | 10 | 13 |
| March 31, 2024 | -6 | 83 | -15 | 8 | -14 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 534 | 415 | 321 | 1 | 0 | 330 | 104 | 5 | 90 | 63 |
| March 31, 2025 | 413 | 342 | 248 | 5 | 0 | 270 | 59 | 1 | 78 | 41 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
